Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.71 |
| ▸ | CNR1 | P21554 | 1/20 | 0.71 |
| ▸ | HTR2B | P41595 | 1/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | ACP1 | P24666 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bazinaprine SCHEMBL10830678 | 0.99 | ACHE (0.98) | ACHECYP3A4CYP1A2CYP2D6LMNA | |
| SCHEMBL29295397 | 0.88 | ACHE (0.78) | ACHECYP3A4CYP1A2CYP2D6LMNA | |
| SCHEMBL1752978 | 0.85 | LMNA (0.80) | ACHECYP3A4CYP1A2CYP2D6LMNA | |
| SCHEMBL10706131 | 0.85 | ACHE (0.73) | ACHECYP3A4CYP1A2CYP2D6LMNA | |
| SCHEMBL1753092 | 0.83 | ACHE (0.75) | ACHECYP3A4CYP1A2CYP2D6LMNA | |
| SCHEMBL14069119 | 0.83 | ACHE (0.75) | ACHECYP3A4CYP1A2CYP2D6LMNA | |
| Minaprine SCHEMBL49371 | 0.83 | ACHE (1.00) | ACHECYP3A4CYP1A2CYP2D6LMNA | |
| Hydrochloric Acid SCHEMBL10830590 | 0.83 | ACHE (0.70) | ACHECYP3A4CYP1A2CYP2D6LMNA | |
| Minaprine SCHEMBL124092 | 0.82 | CYP3A4 (1.00) | ACHECYP3A4CYP1A2CYP2D6LMNA | |
| Minaprine SCHEMBL124094 | 0.82 | CYP3A4 (1.00) | ACHECYP3A4CYP1A2CYP2D6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1001 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4618981-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | Remedi, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| WO-2024108195-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | REMEDI, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| WO-2022159506-A1 | DEUTERATED CANNABIDIOL COMPOUNDS | MERIT THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | claimed |
| WO-2022159507-A1 | COMBINATION OF CANNABINOIDS WITH ADDITIONAL THERAPEUTIC AGENTS FOR TREATING DISEASES OR DISORDERS | MERIT THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| CN-102143961-B | Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity | NEURAXON INC | 2014-11-05 | — | — | CN | claimed |
| US-8703764-B2 | Combination therapy for dementia, depression and apathy | SHELDON LESLIE JAMES (CA) | 2014-04-22 | — | — | US | claimed |
| US-8586620-B2 | Substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2013-11-19 | — | — | US | claimed |
| WO-2012018761-A2 | METHOD OF TREATMENT OF ANDROGEN-MEDIATED CANCERS | CENERX BIOPHARMA, INC. (US) | 2012-02-09 | — | — | WO | claimed |
| JP-2011526251-A | — | — | 2011-10-06 | — | — | JP | claimed |
| WO-2005048999-A2 | USE OF CYCLOOXYGENASE-2 INHIBITORS FOR THE TREATMENT OF DEPRESSIVE DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-06-02 | — | — | WO | claimed |
| US-20030119428-A1 | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors | SCHERING CORPORATION | 2003-06-26 | — | — | US | claimed |
| CN-1370067-A | Use of monoamine oxidase inhibitors for manufacture of drugs intended for treatment of obesity | SANOFI SYNTHELABO (FR) | 2002-09-18 | — | — | CN | claimed |
| EP-1210080-A2 | USE OF MONOAMINE OXIDASE INHIBITORS FOR THE MANUFACTURE OF DRUGS INTENDED FOR THE TREATMENT OF OBESITY | Sanofi-Aventis (FR) | 2002-06-05 | — | — | EP | claimed |
| US-20020019421-A1 | Compositions and therapy for substance addiction | BIBERMAN RONI (IL) | 2002-02-14 | — | — | US | claimed |
| EP-1150715-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING NICOTINE OR A LIGAND OF NICOTINE RECEPTORS AND A MONAMINE OXYDASE INHIBITOR AND THEIR USE FOR TREATING TOBACCO WITHDRAWAL SYMPTOMS | SANOFI-SYNTHELABO (FR) | 2001-11-07 | — | — | EP | claimed |
| EP-1078632-A1 | Use of monoamine oxydase inhibitors for the manufacture of drugs intended for the treatment of obesity | SANOFI-SYNTHELABO (FR) | 2001-02-28 | — | — | EP | claimed |
| WO-2001012176-A2 | USE OF MONOAMINE OXIDASE INHIBITORS FOR THE MANUFACTURE OF DRUGS INTENDED FOR THE TREATMENT OF OBESITY | SANOFI-SYNTHELABO (FR) | 2001-02-22 | — | — | WO | claimed |
| WO-2000045846-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING NICOTINE OR A LIGAND OF NICOTINE RECEPTORS AND A MONAMINE OXYDASE INHIBITOR AND THEIR USE FOR TREATING TOBACCO WITHDRAWAL SYMPTOMS | SANOFI-SYNTHELABO (FR) | 2000-08-10 | — | — | WO | claimed |
| WO-1999013879-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A MONOAMINE OXYDASE INHIBITOR AND THEIR USE IN THERAPY | SANOFI-SYNTHELABO (FR) | 1999-03-25 | — | — | WO | claimed |